EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Effects of GLP‐1 Receptor Agonists in Alcohol Use Disorder

Mette Kruse Klausen iD, Gitte Moos Knudsen iD, Tina Vilsbøll iD, Anders Fink-Jensen iD

Basic & Clinical Pharmacology & Toxicology · 2025-03 · 136 (3)

DOI: 10.1111/bcpt.70004 ↗

At a glance

Übersichtsarbeit in Basic & Clinical Pharmacology & Toxicology, 2025-02. Written by Mette Kruse Klausen and 3 co-authors. Institution: Psychiatric Centre Copenhagen, Mental Health Services in the Capitol Region of Denmark, Copenhagen University Hospital Frederiksberg, Frederiksberg, …. Major MEDLINE topics: Glucagon-Like Peptide-1 Receptor Agonists, Alcoholism, Glucagon-Like Peptides. Cited 26 times so far (Crossref); 132 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Research Fund of the Mental Health Services, Capital Region of Denmark, Novo Nordisk Foundation, Novo Nordisk Fonden.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

In the search for novel treatment strategies for alcohol use disorder (AUD), glucagon‐like peptide‐1 (GLP‐1) receptor agonists (GLP‐1RAs) approved for treating Type 2 diabetes and obesity have caught much attention. GLP‐1 is a naturally occurring peptide produced in the small intestines and the brain, regulating plasma glucose levels and satiety. This focused review will report on the preclinical studies, case stories, register‐based cohort studies, brain‐imaging data and secondary analysis of clinical data supporting the role of GLP‐1RAs as a novel treatment of AUD. Several clinical trials are ongoing, examining the potential effects of the GLP‐1RA semaglutide in AUD.

Subjects

MeSH terms (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsAlcoholismGlucagon-Like PeptidesHumansAnimalsBrainGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide 1Semaglutide

Author keywords

AUDGLP‐1alcohol use disorderfMRIglucagon‐like peptide‐1

Substances

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide 1Semaglutide

Authors and institutions

  • Psychiatric Centre Copenhagen, Mental Health Services in the Capitol Region of Denmark, Copenhagen University Hospital Frederiksberg, Frederiksberg, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Clinical Research, Steno Diabetes Center Copenhagen, Copenhagen, Denmark.

ORCID profiles: Mette Kruse Klausen, Gitte Moos Knudsen, Tina Vilsbøll, Anders Fink-Jensen

Funding

  • Research Fund of the Mental Health Services, Capital Region of Denmark
  • Novo Nordisk Foundation
  • Novo Nordisk Fonden

Cite

APA

Klausen, M. K., Knudsen, G. M., Vilsbøll, T., & Fink-Jensen, A. (2025). Effects of GLP‐1 Receptor Agonists in Alcohol Use Disorder. Basic & Clinical Pharmacology & Toxicology, 136(3). https://doi.org/10.1111/bcpt.70004

Vancouver

Klausen MK, Knudsen GM, Vilsbøll T, Fink-Jensen A. Effects of GLP‐1 Receptor Agonists in Alcohol Use Disorder. Basic & Clinical Pharmacology & Toxicology. 2025;136(3). doi:10.1111/bcpt.70004

BibTeX
@article{Klausen2025,
  author = {Klausen, Mette Kruse and Knudsen, Gitte Moos and Vilsbøll, Tina and Fink-Jensen, Anders},
  title = {Effects of GLP‐1 Receptor Agonists in Alcohol Use Disorder},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2025},
  volume = {136},
  number = {3},
  doi = {10.1111/bcpt.70004}
}
Start for free →